CAMBRIDGE, Mass.–()–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the main RNAi therapeutics firm, in the present day introduced that, for the second yr in a row, Science journal has named the corporate a prime employer in its annual survey of the biotech and pharmaceutical trade.

“We’re thrilled to be named a prime employer by Science for the second yr in a row, as we proceed to construct a top-tier, impartial biopharmaceutical firm based on RNAi,” stated John Maraganore, Ph.D., Chief Government Officer, Alnylam Prescribed drugs. “This continued recognition is a testomony to the efforts of our almost 1,500 workers around the globe who say ‘Problem Accepted’ to advancing RNAi therapeutics as a brand new class of progressive medicines to sufferers in want. It additionally embodies the daring scientific endeavor and pioneering spirit that spurred our founding over 18 years in the past. We’re happy to see our collaborators Regeneron reclaim the highest rating this yr, as we share a dedication to innovation and equally daring science centered on bringing new remedy choices to sufferers.”

Outcomes had been primarily based on 7,650 surveys of individuals within the trade who rated corporations on attributes similar to company picture, management and route, work tradition/atmosphere, and tutorial and mental problem. In keeping with Science, the 2020 world survey outcomes had been primarily based on responses from North America (67 %), Europe (19 %) and the Asia/Pacific Rim (10 %).

Science has lengthy acknowledged leaders in innovation inside our trade, and we’re thrilled to be ranked on this esteemed listing for the second yr in a row amongst our revered friends,” stated Akshay Vaishnaw, M.D., Ph.D., President, Analysis & Improvement, Alnylam Prescribed drugs. “It’s thrilling to have our science and tradition proceed to be acknowledged as we work exhausting to find and develop the following wave of RNAi therapeutics for sufferers with critical illnesses.”

For the whole characteristic and firm rankings, please go to:

About Alnylam Prescribed drugs

Alnylam (Nasdaq: ALNY) is main the interpretation of RNA interference (RNAi) into a complete new class of progressive medicines with the potential to remodel the lives of individuals stricken with uncommon genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular illnesses. Based mostly on Nobel Prize-winning science, RNAi therapeutics symbolize a strong, clinically validated strategy for the remedy of a variety of extreme and debilitating illnesses. Based in 2002, Alnylam is delivering on a daring imaginative and prescient to show scientific chance into actuality, with a strong RNAi therapeutics platform. Alnylam’s business RNAi therapeutic merchandise are ONPATTRO® (patisiran), permitted within the U.S., EU, Canada, Japan, Brazil, and Switzerland, and GIVLAARI® (givosiran), permitted within the U.S., Brazil and the EU. Alnylam has a deep pipeline of investigational medicines, together with six product candidates which can be in late-stage improvement. Alnylam is executing on its “Alnylam 2020” technique of constructing a multi-product, commercial-stage biopharmaceutical firm with a sustainable pipeline of RNAi-based medicines to deal with the wants of sufferers who’ve restricted or insufficient remedy choices. Alnylam is headquartered in Cambridge, MA.

Source link


Write A Comment